Testing a Decision Tool to Adjust Levothyroxine Dose Early
Tests a decision tool that guides early levothyroxine dose changes in adults after thyroid removal.
Plain-language title generated from the registry record
Registry title: Patient-centered Dosage of Levothyroxine
Key facts
- Where
- Bergen, Oslo, and Tromsø, NorwaySee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who start levothyroxine after a total or completion thyroidectomy for thyroid cancer or benign thyroid nodules at Norwegian hospitals. Dosing guided by a decision support tool is compared with usual care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Total or completion thyroidectomy for differentiated thyroid cancer or benign thyroid nodules
- Earlier treatment
- Total or completion thyroidectomy at a Norwegian hospital
Main reasons for not taking part
- Anaplastic thyroid cancer
- Thyroid cancer with distant metastasis
- Graves disease
- Toxic nodules
- Pregnancy
Read by machine on 12 November 2026.
Where in Norway
- Haukeland University HospitalBergen, NorwayContact: Renate Kollevåg Vik, PhDTaking people
- Oslo University HospitalOslo, NorwayContact: Ingrid Alm Andersen, PhDTaking people
- University Hospital of North NorwayTromsø, NorwayContact: Solveig Konst, Cand.MedTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital of North Norway
- Trial code
- NCT06455371
- Record updated
- 10 September 2025
- Original description
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.Read full original descriptionShow less
Patient-centered Decision Support Tool for Levothyroxine Dosage
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.
Inclusion: Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals.
Exclusion: Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy.